RxDoctor Payments Data

Peter Hurlbut-Miller, MD

Retina Specialist · Honolulu, HINPI 1285695940

Payments from drug & device makers

$892in general payments, 2019–2025

Across 36 payments — averaging $24.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$605
  • Alimera Sciences, Inc.$53
  • Regeneron Healthcare Solutions, Inc.$40
  • Mallinckrodt Hospital Products Inc.$32
  • Optos, Inc.$32
  • Apellis Pharmaceuticals, Inc.$28
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$86096%
  • Entertainment$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$938,001
Medicare patients
731
Services billed
11,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept38$77,156
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol49$7,323
Brimonidine Tartrate65$7,150
Prednisolone Acetate157$6,255
CombiganBrimonidine Tartrate/Timolol11$4,216
Latanoprost295$4,166
Brinzolamide11$1,928
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat100$1,613
Ofloxacin109$1,446
Azelastine Hcl14$845
Timolol Maleate75$656
Dorzolamide Hcl26$497
Acetazolamide ErAcetazolamide11$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea$40$77,15638 claims
AbbVieCombigan$21$4,21611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other retina specialist in Honolulu

Where these figures come from

Is this you, or does something look wrong? →